Kane Schaphorst, MD
Pulmonary Disease · Mobile, ALNPI 1518901248
Payments from drug & device makers
Across 294 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- Johnson & Johnson$604
- United Therapeutics Corporation$548
- Regeneron Healthcare Solutions, Inc.$451
- AstraZeneca$375
- Merck$353
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,800100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 73 | $1,712 |
| Johnson & Johnson(2 entities) | 37 | $604 |
| United Therapeutics Corporation | 25 | $548 |
| Regeneron Healthcare Solutions, Inc. | 24 | $451 |
| AstraZeneca(2 entities) | 20 | $375 |
| Merck | 17 | $353 |
| Bayer | 16 | $261 |
| Sanofi | 13 | $253 |
| Astellas Pharma US Inc | 8 | $154 |
| Boehringer Ingelheim | 8 | $153 |
| Electromed, Inc. | 7 | $104 |
| Mallinckrodt Hospital Products Inc. | 4 | $96 |
| Mylan Specialty L.p. | 4 | $70 |
| Sandoz | 4 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Abiomed | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $38 |
| Portola Pharmaceuticals, LLC | 2 | $33 |
| GSK | 2 | $33 |
| Pfizer | 2 | $30 |
| Baxter Healthcare | 1 | $26 |
| Calliditas Therapeutics US Inc. | 1 | $25 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Inogen, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $20 |
| Greenwich Biosciences, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Shionogi Inc | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $17 |
| CSL Behring | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Pulmonx Corporation | 1 | $13 |
| Covidien LP | 1 | $12 |
| Philips North America LLC | 1 | $12 |
How this compares
$5,800 in reported general payments places this provider in the 55th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Mobile
- Allan SeibertMobile$2.4M
- Adrian DivittorioMobile$212K
- Peter LutzMobile$102K
- Johnson HaynesMobile$50K
- Virginia RadcliffMobile$23K
- Brian FoutyMobile$21K
- Cynthia CrowderMobile$20K
- Philip AlmaloufMobile$14K
- Campbell SindelMobile$14K
- Chibuzo OdigweMobile$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.